Upcoming event

Associations between PSA kinetics and cause-specific mortality in patients with localised prostate cancer managed observationally: A sub-group analysis of the SPCG-6 study

  • F.B. Thomsen,
  • K. Brasso,
  • K.D. Berg,
  • T.A. Gerds,
  • J-E. Johansson,
  • A. Angelsen,
  • T.L.J. Tammela and P. Iversen

Publication: European Urology Supplements, Volume 2, Issue 14

PII: S1569-9056(15)60320-7

DOI: 10.1016/S1569-9056(15)60320-7

Commented by Henk van der Poel

Men with non-metastatic prostate cancer randomized to placebo in the SPCG-6 trial had a higher risk of dying of non-PCA related disease (38%) compared to PCA related mortality (31%) at 15 years. Early PSA kinetics after randomization were only useful to predict survival in men with PSA between 10-25ng/ml. The risk of dying of prostate cancer almost doubled when initial PSADT was <3 years (42%) as compared >3 years (25%). Interestingly, in men with higher PSA values at baseline, kinetics had little predictive value for survival.